IOBT

IO Biotech, Inc. IOBT

NasdaqunknownHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-8.38M

Quarter to Sep 30

Free cash flow

$-18.48M

Quarter to Sep 30

Top Institutional Holders

as of Q1 2026
$199.0K total
Ikarian Capital, LLC
$81.4K0.0%
BOOTHBAY FUND MANAGEMENT, LLC
$26.5K0.0%
GSA CAPITAL PARTNERS LLP
$20.0KNew
MARSHALL WACE, LLP
$18.1K-29.8%
XTX Topco Ltd
$15.6K+1575.4%
MORGAN STANLEY
$12.1K-61.8%
MILLENNIUM MANAGEMENT LLC
$11.4K+40.0%
CITIGROUP INC
$4.3K-35.0%
JANE STREET GROUP, LLC
$3.4KNew
Beacon Pointe Advisors, LLC
$2.5K-91.6%
GEODE CAPITAL MANAGEMENT, LLC
$2.0K0.0%
UBS Group AG
$1.8K-28.9%
See all 12 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q3 2025
EDGAR

EPS (Diluted)

Q3 2025
EDGAR

Free Cash Flow

Q3 2025
EDGAR

Debt/Equity

Q3 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IOBT

Earnings Per Share

13fpro.ai/company/IOBT

Loading ratio trend…

About IO Biotech, Inc. (IOBT): stock profile, AI score and financials

IO Biotech, Inc. (IOBT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IOBT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q3 2025), IO Biotech, Inc. reports net income of $-8.4M, free cash flow of $-18.5M. Top institutional holders of IOBT by reported 13-F value include Ikarian Capital, BOOTHBAY FUND MANAGEMENT, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. IOBT trades on the Nasdaq exchange and files with the SEC under CIK 1865494. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOBT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IO Biotech, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1865494 →